Opinion|Videos|March 24, 2025
Current Treatment Landscape for Late-Line RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates and clinical trials of emerging agents, with treatment selection highly individualized based on prior therapies, resistance patterns and patient-specific factors like comorbidities, quality of life considerations and treatment goals.
Advertisement
Video content above is prompted by the following:
- What is the current treatment landscape for patients who have late-line RRMM?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Repeated Injections Double Progression-Free Survival in Glioblastoma
2
GLP-1s: Weight Loss and Survival in Breast Cancer Recovery
3
Balance Exercise Package for Patients With Cancer: Improve Stability With Tandem Standing
4
What Is Angioimmunoblastic T-Cell Lymphoma?
5